1. Home
  2. SCL vs DVAX Comparison

SCL vs DVAX Comparison

Compare SCL & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCL
  • DVAX
  • Stock Information
  • Founded
  • SCL 1932
  • DVAX 1996
  • Country
  • SCL United States
  • DVAX United States
  • Employees
  • SCL N/A
  • DVAX N/A
  • Industry
  • SCL Package Goods/Cosmetics
  • DVAX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SCL Consumer Discretionary
  • DVAX Health Care
  • Exchange
  • SCL Nasdaq
  • DVAX Nasdaq
  • Market Cap
  • SCL 1.1B
  • DVAX 1.3B
  • IPO Year
  • SCL N/A
  • DVAX 2004
  • Fundamental
  • Price
  • SCL $48.63
  • DVAX $9.36
  • Analyst Decision
  • SCL
  • DVAX Buy
  • Analyst Count
  • SCL 0
  • DVAX 4
  • Target Price
  • SCL N/A
  • DVAX $26.50
  • AVG Volume (30 Days)
  • SCL 192.8K
  • DVAX 1.9M
  • Earning Date
  • SCL 10-29-2025
  • DVAX 11-06-2025
  • Dividend Yield
  • SCL 3.16%
  • DVAX N/A
  • EPS Growth
  • SCL 67.06
  • DVAX N/A
  • EPS
  • SCL 2.54
  • DVAX N/A
  • Revenue
  • SCL $2,260,395,000.00
  • DVAX $316,268,000.00
  • Revenue This Year
  • SCL $9.25
  • DVAX $23.23
  • Revenue Next Year
  • SCL $7.93
  • DVAX $16.57
  • P/E Ratio
  • SCL $19.17
  • DVAX N/A
  • Revenue Growth
  • SCL 2.64
  • DVAX 26.66
  • 52 Week Low
  • SCL $44.23
  • DVAX $9.21
  • 52 Week High
  • SCL $82.08
  • DVAX $14.63
  • Technical
  • Relative Strength Index (RSI)
  • SCL 43.42
  • DVAX 32.99
  • Support Level
  • SCL $47.77
  • DVAX $9.51
  • Resistance Level
  • SCL $49.56
  • DVAX $9.94
  • Average True Range (ATR)
  • SCL 1.34
  • DVAX 0.29
  • MACD
  • SCL 0.03
  • DVAX -0.07
  • Stochastic Oscillator
  • SCL 20.19
  • DVAX 12.31

About SCL Stepan Company

Stepan Co manufactures and sells a variety of chemicals and chemical-based products. The company organizes itself into three segments based on product type. The surfactants segment, which generates the majority of revenue, sells cleaning agents used in detergents, shampoos, body wash, fabric softeners, toothpastes, and other personal-care products. The polymers segment sells polyurethane used to manufacture rigid foam for thermal insulation, as well as phthalic anhydride used to make plastic components for the construction, automotive, and boating industries. The specialty products segment sells chemicals used in food and flavoring. The majority of Stepan's revenue comes from the United States, followed by France, Poland, the United Kingdom, Brazil, Mexico, and other countries.

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Share on Social Networks: